SCHEMBL312571

SCHEMBL312571

CCc1ccc(=O)n(-c2ccccc2)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.59
ALDH1A1 P00352 2/20 0.59
KDM4E B2RXH2 2/20 0.59
HPGD P15428 1/20 0.59
BLM P54132 1/20 0.59
HSD17B10 Q99714 1/20 0.59
L3MBTL1 Q9Y468 2/20 0.42
ALOX15B O15296 1/20 0.42
CYP3A4 P08684 1/20 0.42
GAA P10253 1/20 0.42
CYP2D6 P10635 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
TP53 P04637 1/20 0.41
GABRA2 P47869 2/20 0.40
GABRB2 P47870 2/20 0.40
MGLL Q99685 2/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
NPC1 O15118 3/20 0.39
RAB9A P51151 3/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6536599 0.93 CYP1A2 (0.53) CYP1A2ALDH1A1KDM4EHPGDBLM
SCHEMBL5697621 0.87 CYP1A2 (0.46) CYP1A2ALDH1A1KDM4EHPGDBLM
SCHEMBL15964171 0.86 ALDH1A1 (0.56) CYP1A2ALDH1A1KDM4EHPGDBLM
SCHEMBL14464201 0.82 ESR1 (0.43) CYP1A2ALDH1A1KDM4EHPGDBLM
SCHEMBL23619123 0.81 ALDH1A1 (0.55) CYP1A2ALDH1A1KDM4EHPGDBLM
SCHEMBL147797 0.81 KDM4E (0.55) CYP1A2ALDH1A1KDM4EHPGDBLM
SCHEMBL3729672 0.81 ALDH1A1 (0.55) CYP1A2ALDH1A1KDM4EHPGDBLM
SCHEMBL14194615 0.81 KDM4E (0.55) CYP1A2ALDH1A1KDM4EHPGDBLM
SCHEMBL146809 0.81 ALDH1A1 (0.55) CYP1A2ALDH1A1KDM4EHPGDBLM
SCHEMBL146271 0.81 ALDH1A1 (0.54) CYP1A2ALDH1A1KDM4EHPGDBLM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4514348-A2 PREVENTION AND TREATMENT OF POST-OPERATIVE COGNITIVE DYSFUNCTION (POCD) Noetix Pharma LLC (US) 2025-03-05 EP claimed
US-20240299698-A1 PREVENTION AND TREATMENT OF POST-OPERATIVE COGNITIVE DYSFUNCTION (POCD) NOETIX PHARMA LLC 2024-09-12 US claimed
WO-2023211684-A2 PREVENTION AND TREATMENT OF POST-OPERATIVE COGNITIVE DYSFUNCTION (POCD) NOETIX PHARMA LLC (US) 2023-11-02 WO claimed
EP-2262501-B1 TREATMENT OF SEPSIS WITH 5-ETHYL-1-PHENYL-2(1H)-PYRIDONE SOLANAN INC (US) 2014-08-13 EP claimed
US-20120071518-A1 Treatment of Sepsis with 5-Ethyl-1-Phenyl-2(1H)-Pyridone SOLANAN, INC. (US) 2012-03-22 US claimed
US-8093210-B2 Treatment of sepsis with 5-ethyl-1-phenyl-2(1H)-pyridone SOLANAN, INC. (US) 2012-01-10 US claimed
US-20110092549-A1 Treatment of Sepsis with 5-Ethyl-1-Phenyl-2(1H)-Pyridone SOLANAN, INC. (US) 2011-04-21 US claimed
EP-2262501-A2 TREATMENT OF SEPSIS WITH 5-ETHYL-1-PHENYL-2(1H)-PYRIDONE AND NOVEL METHODS FOR SYNTHESIS Solanan, Inc. (US) 2010-12-22 EP claimed
WO-2009111785-A2 TREATMENT OF SEPSIS WITH 5-ETHYL-1-PHENYL-2(1H)-PYRIDONE AND NOVEL METHODS FOR SYNTHESIS SOLANAN, INC. (US) 2009-09-11 WO claimed
EP-0866656-B1 USE OF N-SUBSTITUTED PYRIDONES AS TUMOR NECROSIS FACTOR ALPHA INHIBITORS MARGOLIN SOLOMON B (US) 2007-04-25 EP claimed
EP-1242084-B1 TREATMENT OF BREAST CARCINOMAS, ASTROCYTOMAS, MELANOMAS AND RELATED TUMORS MARGOLIN SOLOMON B (US) 2006-07-05 EP claimed
EP-1261338-B1 COMPOSITIONS AND METHODS FOR TREATMENT OF EPILEPSY CYMAR INC (US) 2006-06-14 EP claimed
US-6956044-B1 Compositions and methods for treatment of epilepsy INTERMUNE, INC. 2005-10-18 US claimed
EP-1069898-B1 TOPICAL ANTISEPTIC COMPOSITIONS AND METHODS MARGOLIN SOLOMON B (US) 2004-05-12 EP claimed
EP-0813409-B1 TREATMENT OF CYTOKINE GROWTH FACTOR CAUSED DISORDERS MARGOLIN SOLOMON B (US) 2004-05-06 EP claimed
EP-0702551-B1 COMPOSITIONS AND METHODS FOR REPARATION AND PREVENTION OF FIBROTIC LESIONS MARGOLIN SOLOMON B (US) 2002-09-25 EP claimed
US-5962478-A ADMINISTERING A N-SUBSTITUTED 2(1H)PYRIDONE INTERMUNE, INC. 1999-10-05 US claimed
US-20250367178-A1 AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF AVALYN PHARMA INC (US) 2025-12-04 US disclosed
US-4042699-A 5-METHYL-1-PHENYL-2-(1H)-PYRIDONE AFFILIATED MEDICAL RESEARCH, INC. (US) 1977-08-16 US disclosed
US-3974281-A ANALGESICS, ANTI-PYRETIC AND ANTI-INFLAMMATORY AGENTS AFFILIATED MEDICAL RESEARCH, INC. (US) 1976-08-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240299698-A1 PREVENTION AND TREATMENT OF POST-OPERATIVE COGNITIVE DYSFUNCTION (POCD) CHAT, PNPO, PLPBP CYP1A2 486/4885ALDH1A1 1343/4885KDM4E 3737/4885
US-20120071518-A1 Treatment of Sepsis with 5-Ethyl-1-Phenyl-2(1H)-Pyridone SELP, PSPH, PLPBP CYP1A2 271/4885ALDH1A1 1737/4885KDM4E 1751/4885
US-20250367178-A1 AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF PLPBP, PIR, PDXK CYP1A2 123/4885ALDH1A1 167/4885KDM4E 2879/4885
US-20110092549-A1 Treatment of Sepsis with 5-Ethyl-1-Phenyl-2(1H)-Pyridone SELP, PSPH, PLPBP CYP1A2 271/4885ALDH1A1 1737/4885KDM4E 1751/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.